On February 28, 2007, the Board of Directors (the “Board”) of Adeza Biomedical Corporation (the “Company”) approved increases to the base salaries for the Company’s named executive officers (as defined in Item 402 of Regulation S-K promulgated by the Securities and Exchange Commission). The Compensation Committee of the Board determines the annual salary adjustments of the Company’s named executive officers by evaluating the competitive marketplace, the performance of the Company, the performance of each executive and the operational areas of the Company for which that executive is responsible, and the responsibilities assumed by that executive. Each of the named executive officers received a merit increase in base salary, retroactive to February 1, 2007. The base salaries for the named executive officers retroactive to February 1, 2007, are as set forth across from each such officer’s name below:

				Base Salary Retroactive
Name		Title		to February 1, 2007
Emory V. Anderson		President and Chief Executive Officer		$	402,251
Mark D. Fischer-Colbrie		SVP, Finance and Administration and Chief Financial Officer		$	280,027
Durlin E. Hickok		SVP, Medical Affairs		$	276,203
Marian E. Sacco		SVP, Sales and Marketing		$	280,399
Robert O. Hussa		Vice President, Research and Development		$	215,955